Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Sep;30(5):746-55.
doi: 10.1007/s10875-010-9424-3. Epub 2010 May 1.

B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease

Collaborators, Affiliations
Multicenter Study

B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease

Gaël Mouillot et al. J Clin Immunol. 2010 Sep.

Abstract

Background: Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by recurrent infections and defective immunoglobulin production.

Methods: The DEFI French national prospective study investigated peripheral T-cell and B-cell compartments in 313 CVID patients grouped according to their clinical phenotype, using flow cytometry.

Results: In patients developing infection only (IO), the main B-cell or T-cell abnormalities were a defect in switched memory B cells and a decrease in naive CD4(+) T cells associated with an increase in CD4(+)CD95(+) cells. These abnormalities were more pronounced in patients developing lymphoproliferation (LP), autoimmune cytopenia (AC), or chronic enteropathy (CE). Moreover, LP and AC patients presented an increase in CD21(low) B cells and CD4(+)HLA-DR(+) T cells and a decrease in regulatory T cells.

Conclusion: In these large series of CVID patients, the major abnormalities of the B-cell and T-cell compartments, although a hallmark of CVID, were only observed in half of the IO patients and were more frequent and severe in patients with additional lymphoproliferative, autoimmune, and digestive complications.

PubMed Disclaimer

References

    1. Eur J Immunol. 2000 Sep;30(9):2632-8 - PubMed
    1. Blood. 2008 Jul 15;112(2):277-86 - PubMed
    1. Clin Exp Immunol. 2002 Aug;129(2):346-53 - PubMed
    1. Clin Infect Dis. 2008 May 15;46(10):1547-54 - PubMed
    1. Clin Exp Immunol. 2007 Mar;147(3):521-5 - PubMed

Publication types

MeSH terms

LinkOut - more resources